INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Hyep Ivan sold BCAX

Chief Financial Officer · Bicara Therapeutics Inc. · Common Stock

Side
SELL
Value
$212K
Shares
9,200
Price
$23
Executed
Apr 21, 2026
Disclosed
Apr 22, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Apr 21 executedApr 22, 2026 disclosed

BCAX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+8 / 25

    $212K reported value · 6.0% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    4 prior trades recorded in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BCAX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    HI
    Hyep IvanChief Financial Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$35K
    9,200 sh
    		Apr 21, 2026Apr 22, 2026
    traded Apr 21, 2026
    		+1dSEC FORM 4

    Evidence

    3
    HI
    Hyep IvanChief Financial Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M—
    9,200 sh
    		Apr 21, 2026Apr 22, 2026
    traded Apr 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,454 sh
    		Apr 16, 2026Apr 20, 2026
    traded Apr 16, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$36K
    8,226 sh
    		Apr 16, 2026Apr 20, 2026
    traded Apr 16, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$28K
    7,454 sh
    		Apr 16, 2026Apr 20, 2026
    traded Apr 16, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M—
    15.0K sh
    		Apr 20, 2026Apr 20, 2026
    traded Apr 20, 2026
    		+0dSEC FORM 4

    Evidence

    0
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$57K
    15.0K sh
    		Apr 20, 2026Apr 20, 2026
    traded Apr 20, 2026
    		+0dSEC FORM 4

    Evidence

    12
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$354K
    15.0K sh
    		Apr 20, 2026Apr 20, 2026
    traded Apr 20, 2026
    		+0dSEC FORM 4

    Evidence

    0
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M—
    8,226 sh
    		Apr 16, 2026Apr 20, 2026
    traded Apr 16, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$39K
    7,080 sh
    		Apr 16, 2026Apr 20, 2026
    traded Apr 16, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MC
    Mazumdar ClaireDirector, Chief Executive Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,080 sh
    		Apr 16, 2026Apr 20, 2026
    traded Apr 16, 2026
    		+4dSEC FORM 4

    Evidence

    0
    RD
    Raben DavidChief Medical Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$21K
    5,500 sh
    		Mar 25, 2026Mar 26, 2026
    traded Mar 25, 2026
    		+1dSEC FORM 4

    Evidence

    8
    RD
    Raben DavidChief Medical Officer
    BCAXBicara Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$104K
    5,500 sh
    		Mar 25, 2026Mar 26, 2026
    traded Mar 25, 2026
    		+1dSEC FORM 4

    Evidence

    0
    RD
    Raben DavidChief Medical Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M—
    5,500 sh
    		Mar 25, 2026Mar 26, 2026
    traded Mar 25, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CR
    Cohlhepp RyanDirector, President and COO
    BCAXBicara Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$69K
    3,828 sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    0
    HI
    Hyep IvanChief Financial Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$7,132
    1,882 sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    6
    HI
    Hyep IvanChief Financial Officer
    BCAXBicara Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$34K
    1,882 sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    0
    HI
    Hyep IvanChief Financial Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,882 sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    0
    HI
    Hyep IvanChief Financial Officer
    BCAXBicara Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$35K
    9,200 sh
    		Dec 22, 2025Dec 23, 2025
    traded Dec 22, 2025
    		+1dSEC FORM 4

    Evidence

    13
    HI
    Hyep IvanChief Financial Officer
    BCAXBicara Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$168K
    9,200 sh
    		Dec 22, 2025Dec 23, 2025
    traded Dec 22, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-026604
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 21, 2026
    Published
    Apr 22, 2026
    Ingested by INSIDER
    Nov 5, 04:03 UTC
    Last re-read
    Nov 5, 04:03 UTC

    Extracted facts

    Filer
    Hyep Ivan
    Role
    Chief Financial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Bicara Therapeutics Inc.
    Ticker
    BCAX
    Shares
    9,200
    Price per share
    $23
    Value
    $211,614
    Execution date (reported)
    Apr 21, 2026
    Owned after transaction
    145.4K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 9,200
    • Price: $23.0015

    = $211,614

    What this establishes

    Hyep Ivan filed this Form 4 reporting a open-market sale of BCAX on Apr 21, 2026. It became public on Apr 22, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Hyep Ivancik:0002034668
    Issuer
    Bicara Therapeutics Inc.cik:0002023658

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.